Tesamorelin
Several randomized clinical trials have shown the beneficial effects of tesamorelin on impaired body composition in patients with HIV-associated lipodystrophy [39-42]. A meta-analysis including four clinical studies also revealed that tesamorelin decreased visceral fat and increased lean body mass. As a result, the FDA approved tesamorelin (Egrifta®) as the first-line treatment for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.